Nflicts of Interest section in Information and facts for Contributors.Employment or Leadership Position: None Consultant or Advisory Function: Steven Horwitz, Celgene (C), Allos Therapeutics (C), Seattle Genetics (C), Bristol-Myers Squibb (C), Genzyme (C), Kyowa Hakko Kirin Pharma (C), Janssen (C), Millennium Pharmaceuticals (C), Hospira (C) Stock Ownership: None Honoraria: None Study Funding: Steven Horwitz, Celgene, Allos Therapeutics, Seattle Genetics, Infinity Pharmaceuticals, Kyowa Hakko Kirin Pharma, Millennium Pharmaceuticals Professional Testimony: None Other Remuneration: NoneAUTHOR CONTRIBUTIONSManuscript writing: All authors Final approval of manuscript: All authors25. Dueck G, Chua N, Prasad A, et al: Interim report of a phase two clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer 116:45414548, 2010 26. Dang NH, Pro B, Hagemeister FB, et al: Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol 136: 439-447, 2007 26a. Enblad G, Hagberg H, Erlanson M, et al: A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 103:2920-2924, 2004 27. Coiffier B, Pro B, Prince HM, et al: Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma just after prior systemic therapy. J Clin Oncol 30:631-636, 2012 28. O’Connor OA, Pro B, Pinter-Brown L, et al: Pralatrexate in individuals with relapsed or refractory peripheral T-cell lymphoma: Results from the pivotal PROPEL study. J Clin Oncol 29:1182-1189, 2011 28a. Coiffier B, Pro B, Prince M, et al: Romidepsin induces durable responses in sufferers with peripheral T-cell lymphoma: GPI-06-0002 study update. 54th Annual Meeting with the American Society of Hematology, Atlanta, GA, December 8-11, 2012 (abstr 3641) 29. Pro B, Advani R, Brice P, et al: Brentuximab vedotin (SGN-35) in individuals with relapsed or refractory systemic anaplastic large-cell lymphoma: Results of a phase II study. J Clin Oncol 30:2190-2196, 2012 30. Arkenau HT, Chong G, Cunningham D, et al: Gemcitabine, cisplatin and methylprednisolone for the remedy of individuals with peripheral T-cell lymphoma: The Royal Marsden Hospital practical experience. Haematologica 92:271-272, 2007 31. Crump M, Shepherd L, Lin B: A randomized phase III study of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin as salvage chemotherapy followed by posttransplantation rituximab upkeep therapy versus observation for treatment of aggressive B-cell and T-cell non-Hodgkin’s lymphoma.SecinH3 Apoptosis Clin Lymphoma six:56-60, 2005 32.Fmoc-D-Glu(OtBu)-OH Cancer Horwitz S MC, Kewalramani T, et al: Secondline therapy with ICE followed by high dose therapy and autologous stem cell transplantation for relapsed/refractory peripheral T-cell lymphomas: Minimal advantage when analyzed by intent to treat.PMID:24624203 Blood 106, 2005 (abstr 2679) 33. Damaj G, Gressin R, Bouabdallah K, et al: Benefits from a potential, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: The BENTLY trial. J Clin Oncol 31:104-110,JOURNAL OF CLINICAL ONCOLOGY
Co-culture of cells is of terrific value for studying interaction of cells. In some coculture research, cells of distinctive forms are seeded within the same mixture as well as the separation distance is sufficiently tiny for them to touch each other, when in other cases, diverse cells are physically separated.1,2 In standard non.